Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2012

View Archived Issues

Fifth phase III study of QVA-149 meets primary endpoint

New Afinitor formulation approved in U.S.

Creabilis products show promise as topical analgesics

PAR1 receptor antagonist prevents heart failure-induced atrial remodeling

Topical cream improves female sexual arousal disorder in phase III trial

Research at Kyowa Hakko Kirin produces new calcium channel antagonists

Merck KGaA patents novel protein kinase inhibitors

Novel inhibitors of JAK3 presented

New heat shock protein inhibitors designed in Japan

Lead product for Parkinson's disease advances through preclinical studies

Zinc peptidase implicated in ACS pathogenesis

Humira indication broadened in Europe

Enrollment complete in phase Ib trial of CALAA-01

ARIAD submits MAA to EMA

PharmaMar product gets orphan drug designation

Exelixis provides update on FDA meeting for cabozantinib

Infradure tissue implant cleared for two hepatitis C trials in Israel

Genmab and Janssen Biotech form worldwide agreement

New drug approved for IBS-C and CIC

Sunovion signs definitive acquisition agreement

FDA grants orphan drug designation to ARLN-05

Lead Nordic Nanovector product clear to enter clinic

Bayer HealthCare submits NDA for regorafenib

New genetic test predicts response to antipsychotics/antidepressants

PR-610 enters phase I/II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...